A randomized phase II study of erdafitinib (ERDA) versus intravesical   chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder   cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after   Bacillus Calmette-Guerin (BCG) therapy

Document type:: Meeting Abstract
Author(s):: Steinberg, Gary D.; Palou-Redorta, Joan; Gschwend, Juergen E.; Ben Tran, B; Loriot, Yohann; Daneshmand, Siamak; Roupret, Morgan; Santiago-Walker, Ademi E.; Switzky, Julie C.; Major, Christopher; Baig, Mahadi; Xia, Qi; Catto, James W. F.
Title:: A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guerin (BCG) therapy
Journal title abbreviation:: J Clin Oncol
Year:: 2020
Journal volume:: 38 Suppl S
Journal issue:: 6
Print-ISSN:: 0732-183X
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: